Binnopharm Group will start selling two hormonal drugs for the treatment of endometriosis in Russia in May this year, and in the future will consider localization of their production. Now the company is actively building a gynecological portfolio, which will include these and several other drugs. In the coming year, the company plans to launch a total of fiv...

Binnopharm Group's export revenue in 2024 reached ₽3.8 billion. The main contribution to this growth was made by key markets - Kazakhstan, Kyrgyzstan and Uzbekistan, where the volume of supplies increased by 30%. This was possible due to successful registration of new drugs and portfolio expansion, as well as active promotion and interaction with the medical...

Binnopharm Group plans to start supplying drugs to the Iraqi market. First drugs have already been identified for registration and subsequent deliveries, the annual turnover of which is estimated at $500 thousand. The first delivery is planned to be made in the fourth quarter of 2025. Binnopharm Group's products are available in 13 countries, including Kazak...

Sistema's net profit for the first 9 months of 2024 was ₽1.8 billion, while a loss of ₽2.6 billion was recorded in the 3rd quarter of 2024 due to an increase in interest expenses. Revenue for the first 9 months increased to ₽888.3 billion, which is 20.1% more than in the same period last year.